Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 24Recruiting 18Completed 4Suspended 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1

Interventions

pembrolizumab 11Nivolumab 6fludarabine phosphate 5fludarabine 5Paclitaxel 5Cyclophosphamide 5Cisplatin 5Cetuximab 5Carboplatin 5atezolizumab 4Specimen Handling 4Pemetrexed 4Docetaxel 4Bevacizumab 4durvalumab 3Magnetic Resonance Spectroscopy 3Ipilimumab 3venetoclax 2temsirolimus 2niraparib 2ibrutinib 2enzalutamide 2encorafenib 2binimetinib 2Trastuzumab 2Taxes 2Standard of Care 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × olaparib × 30 days × Clear all
NCT04729387 2026-06-04

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Novartis

Phase 3 Terminated
358 enrolled 19 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡